# TARA-002 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tara-002

> The next catalyst for TARA-002, sponsored by Protara Therapeutics, Inc. (TARA), is its primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TARA-002 |
| Codes | TARA-002 |
| Sponsor | Protara Therapeutics, Inc. (TARA) https://sec-api.dev/companies/tara/catalysts |
| Indications | carcinoma in situ or cis, macrocystic and mixed cystic lms, cancer and rare diseases, today, macrocystic and mixed-cystic lms, [non-muscle invasive bladder cancer](https://sec-api.dev/indications/non-muscle-invasive-bladder-cancer), Bladder (Urothelial, Transitional Cell) Cancer, [Lymphatic Malformation](https://sec-api.dev/indications/lymphatic-malformation) |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### Oct 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: macrocystic and mixed-cystic LMs.
- First seen 2025-03-05, last confirmed 2026-03-10.
- SEC Form 10-K (accession 0001213900-26-025433): "In October 2023, we initiated the STARBORN-1 trial, a Phase 2 single arm, open-label clinical trial to evaluate the safety and efficacy of TARA-002 in approximately 30 pediatric patients ages six months to less than 18 years old with macrocystic and mixed-cystic LMs." https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/ea0277639-10k_protara.htm
- SEC Form 10-K (accession 0001213900-25-020368): "In October 2023, we initiated STARBORN-1, which is a Phase 2 single-arm, open-label, prospective clinical trial to evaluate the safety and efficacy of intracystic injection of TARA-002 for the treatment of macrocystic and mixed-cystic LMs (≥ 50% macrocystic disease) in participants six months to less than 18 years of age in the U.S. Including an age de-escalation safety lead-in, the clinical trial will enroll approximately 30 patients who will receive up to four injections of TARA-002 spaced approximately six weeks apart." https://www.sec.gov/Archives/edgar/data/1359931/000121390025020368/ea0231646-10k_protara.htm
- SEC Form 10-K (accession 0001213900-25-020368): "In October 2023, we initiated the STARBORN-1 trial, a Phase 2 single arm, open-label clinical trial to evaluate the safety and efficacy of TARA-002 in approximately 30 pediatric patients ages 6 months to less than 18 years old with macrocystic and mixed-cystic" https://www.sec.gov/Archives/edgar/data/1359931/000121390025020368/ea0231646-10k_protara.htm

### Q4 2024: interim data readout

- Status: scheduled. Date confidence: quarter. Indication: non-muscle invasive bladder cancer.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-24-096243): "On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024" https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-24-096243): ""Notably, we remain on track to report interim data in the fourth quarter of 2024 from our ADVANCED-2 study of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC)." https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm

### Dec 2024: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-003026): "December 2024, the Company reported positive interim results from its ongoing Phase 2 open-label" https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea022745701ex99-2_protara.htm

### Q1 2025: trial start

- Status: delayed. Date confidence: quarter. Stage: 3.
- First seen 2024-11-12, last confirmed 2025-03-05.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-020366): "Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025" https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea023264101ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-003026): ""In addition, we expect to begin the pivotal THRIVE-3 study of intravenous (IV) Choline Chloride in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea022745701ex99-2_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-24-096243): "The Company expects to begin dosing patients in the THRIVE-3 registrational trial in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-003026): "Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025" https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea022745701ex99-2_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-020366): "Company plans to initiate THRIVE-3, a registrational Phase 3 clinical trial, in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea023264101ex99-1_protara.htm

### 1H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-24-096243): "Finally, we continue to expect interim data in the first half of 2025 from our ongoing Phase 2 STARBORN-1 trial of TARA-002 in lymphatic malformations (LMs), a rare condition primarily impacting children for which there are no FDA approved therapies."" https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm

### late 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-11-10, last confirmed 2025-11-10.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-107873): "The Company now expects to initiate dosing in THRIVE-3, a registrational Phase 3 clinical trial, by the end of 2025 due to administrative and funding challenges in academic sites in the U.S." https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-107873): "Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support now expected by year-end 2025" https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-11-10, last confirmed 2025-11-10.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-107873): "Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025" https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm

### November 19, 2025: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-12-05, last confirmed 2025-12-05.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-112383): "TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive interim results from its ongoing Phase 2 open-label STARBORN-1 trial assessing intracystic injection of TARA-002, the Company's investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs)." https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/ea026638401ex99-2_protara.htm
- SEC prospectus (424B) (accession 0001213900-25-118744): "November 2025, we announced positive interim results from our ongoing Phase 2 STARBORN-1 trial evaluating TARA-002 in pediatric patients with macrocystic and mixed cystic LMs." https://www.sec.gov/Archives/edgar/data/1359931/000121390025118744/ea0268632-424b5_protara.htm
- SEC prospectus (424B) (accession 0001213900-25-118304): "November 2025, we announced positive interim results from our ongoing Phase 2 STARBORN-1 trial evaluating TARA-002 in pediatric patients with macrocystic and mixed cystic LMs." https://www.sec.gov/Archives/edgar/data/1359931/000121390025118304/ea026827702-424b5_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-020366): "Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025" https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea023264101ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-020366): "Interim results from approximately 25 six-month evaluable BCG-Unresponsive patients are expected to be announced by the end of 2025." https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea023264101ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-040809): "Interim results from approximately 25 six-month evaluable BCG-Unresponsive patients are expected to be announced by the end of 2025." https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/ea024092901ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-035785): "On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025" https://www.sec.gov/Archives/edgar/data/1359931/000121390025035785/ea023968901ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-003026): "Initial data from 12-month evaluable NMIBC patients in ADVANCED-2 trial expected in mid-2025; Results from a futility analysis of approximately" https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea022745701ex99-2_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-24-105782): ""We believe these encouraging data together with our international site expansion will accelerate patient enrollment, and we look forward to reporting initial data from 12-month evaluable patients in mid-2025."" https://www.sec.gov/Archives/edgar/data/1359931/000121390024105782/ea022370601ex99-2_protara.htm
- SEC Form 10-K (accession 0001213900-25-020368): "We anticipate sharing interim 12-month data from the ADVANCED-2 trial by mid-2025 and results from a interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025." https://www.sec.gov/Archives/edgar/data/1359931/000121390025020368/ea0231646-10k_protara.htm

### December 4, 2025: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-08-11, last confirmed 2025-12-05.
- SEC prospectus (424B) (accession 0001213900-25-118744): "December 4, 2025, we presented updated interim data from our ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) NMIBC at a poster session at the 2025 Annual Meeting of the Society of Urologic Oncology (SUO) Conference, reporting positive results that continue to support TARA-002's potential as a mainstay in the NMIBC treatment landscape and demonstrating meaningful and durable activity in BCG-Na&iuml;ve NMIBC patients." https://www.sec.gov/Archives/edgar/data/1359931/000121390025118744/ea0268632-424b5_protara.htm
- SEC prospectus (424B) (accession 0001213900-25-118304): "December 4, 2025, we presented updated interim data from our ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) NMIBC at a poster session at the 2025 Annual Meeting of the Society of Urologic Oncology (SUO) Conference, reporting positive results that continue to support TARA-002's potential as a mainstay in the NMIBC treatment landscape and demonstrating meaningful and durable activity in BCG-Na&iuml;ve NMIBC patients." https://www.sec.gov/Archives/edgar/data/1359931/000121390025118304/ea026827702-424b5_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-107873): ""We continue to make progress in our ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) and remain on track to report interim results from approximately 25 BCG-Unresponsive patients in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-073937): ""We continue to execute on our ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) and look forward to presenting interim results in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/ea025050901ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-107873): "Expect to present interim analysis from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing ADVANCED-2 trial in 1Q 2026" https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-107873): "The Company anticipates reporting interim results from approximately 25 six-month evaluable NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are BCG-Unresponsive in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-073937): "Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026" https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/ea025050901ex99-1_protara.htm

### February 27, 2026: interim data readout

- Status: scheduled. Date confidence: exact. Stage: 2. Indication: carcinoma in situ or CIS.
- First seen 2026-02-24, last confirmed 2026-02-24.
- SEC Form 8-K (accession 0001213900-26-019617): "On February 27, 2026, the Company will present updated interim data from its ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1)" https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/ea0277972-8k_protara.htm

### 2H 2026: trial start

- Status: scheduled. Date confidence: half.
- First seen 2026-02-24, last confirmed 2026-03-10.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025432): "We remain on track to complete enrollment in our BCG-Unresponsive registrational cohort in the ADVANCED-2 trial and to initiate the ADVANCED-3 registrational trial in BCG-Na&iuml;ve patients in the second half of 2026."" https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025432): "On track to initiate the ADVANCED-3 registrational trial in BCG-Na&iuml;ve patients in 2H 2026" https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-019617): "Enrollment is complete in the BCG-Na&iuml;ve cohort of the ADVANCED-2 trial with 31 patients, and the Company remains on track to initiate the ADVANCED-3 registrational trial in BCG-Na&iuml;ve patients in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/ea027797201ex99-1_protara.htm

### Q4 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-03-10, last confirmed 2026-11-06.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-087506): "THRIVE-3, the Company's registrational Phase 3 clinical trial, is ongoing, and the Company expects to report interim results in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea029923601ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-055462): "THRIVE-3, the Company's registrational Phase 3 clinical trial, is ongoing, and the Company expects to report interim results in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea028858101ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025432): "THRIVE-3, the Company's registrational Phase 3 clinical trial, is ongoing, and the Company expects to report interim results in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-116607): "Completed enrollment of THRIVE-3 Phase 2b dosing cohort evaluating IV Choline Chloride in patients dependent on long-term parenteral support; remain on track to report interim results by year-end 2026" https://www.sec.gov/Archives/edgar/data/1359931/000121390026116607/ea030956701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-116607): "Company remains on track to report interim results from the Phase 2b portion of THRIVE-3 in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390026116607/ea030956701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-087506): "On track to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 4Q 2026" https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea029923601ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025432): "Expect to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 2H 2026" https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-055462): "Chloride remains on track, and we expect to announce interim results in the second half of 2026."" https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea028858101ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025432): "Chloride for patients on parenteral support remains on track, with interim results expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Lymphatic Malformation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05871970 (Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Protara Therapeutics." https://clinicaltrials.gov/study/NCT05871970

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Lymphatic Malformation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05871970 (Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Protara Therapeutics." https://clinicaltrials.gov/study/NCT05871970

### 2H 2027: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2026-05-13, last confirmed 2026-11-06.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-116607): "Enrollment in registrational STARBORN-1 trial now expected to complete in early 1Q'2027; expect to initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027" https://www.sec.gov/Archives/edgar/data/1359931/000121390026116607/ea030956701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-116607): "Based on engagement with the FDA under the Breakthrough Therapy designation, the Company expects to initiate a rolling BLA submission for TARA-002 in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1359931/000121390026116607/ea030956701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-087506): "Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027" https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea029923601ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-055462): ""We intend to submit a BLA for TARA-002 in LMs based on the results of the pivotal STARBORN-1 trial in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea028858101ex99-1.htm
- SEC prospectus (424B) (accession 0001213900-26-062153): "FDA, we intend to submit a Biologics License Application for TARA-002 in LMs based on the results of the pivotal STARBORN-1 trial in the second half of 2027 and will continue to submit safety and efficacy data from the trial on an ongoing basis to support the FDA's evaluation of the risks and benefits of TARA-002 in LMs." https://www.sec.gov/Archives/edgar/data/1359931/000121390026062153/ea0292362-424b5_protara.htm

### April 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Protara Therapeutics." https://clinicaltrials.gov/study/NCT07480356

### Apr to Jul 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Protara Therapeutics." https://clinicaltrials.gov/study/NCT07480356

## Same indication

- [NDV-01](https://sec-api.dev/pdufa/ndv-01) (RLMD)
- [Ndv-01 (sustained-release gemcitabine-docetaxel)](https://sec-api.dev/pdufa/ndv-01-sustained-release-gemcitabine-docetaxel) (RLMD)

Calendar months: [February 2026](https://sec-api.dev/fda-calendar/2026-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tara-002.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TARA-002 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tara-002

```bibtex
@misc{secapidev_pdufa_tara_002_20261116,
  title        = {TARA-002 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tara-002}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tara_002_20261116","title":"TARA-002 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tara-002","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
